<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="17">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on March 04, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04994795</url>
  </required_header>
  <id_info>
    <org_study_id>SGDLIV</org_study_id>
    <nct_id>NCT04994795</nct_id>
  </id_info>
  <brief_title>Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer</brief_title>
  <acronym>DEEP-Lung-IV</acronym>
  <official_title>Deep Learning-Enabled Exploration of Predictive Signatures in a Multicenter Retrospective and Prospective Observational Study Allowing the Analysis of the Aggregation of Multimodal Clinical, Biological, Genomic and Radiomics Data Associated With the Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sophia Genetics SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sophia Genetics SAS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Predicting response to therapy and disease progression in stage IV NSCLC patients treated&#xD;
      with pembrolizumab monotherapy, chemotherapy-pembrolizumab combination therapy or&#xD;
      chemotherapy alone in the first-line setting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2021</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment response at first evaluation</measure>
    <time_frame>6-12 weeks after treatment start</time_frame>
    <description>Predict treatment response at first evaluation using baseline data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>Through study completion, expected 6-14 months contingent on cohort</time_frame>
    <description>Predict Progression-Free Survival (PFS) using data at baseline and first evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Through study completion, expected 8-20 months contingent on cohort</time_frame>
    <description>Predict Overall Survival (OS) using data at baseline and first evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Through study completion, expected 6-14 months contingent on cohort</time_frame>
    <description>Predict Duration of Response (DoR) using data at baseline and first evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-To-Progression</measure>
    <time_frame>Through study completion, expected 6-14 months contingent on cohort</time_frame>
    <description>Predict Time-To-Progression (TTP) using data at baseline and first evaluation</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Non-small Cell Lung Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab monotherapy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy and pembrolizumab combination therapy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy doublet</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Predictive models (data collection)</intervention_name>
    <description>Machine learning predictive models</description>
    <arm_group_label>Chemotherapy and pembrolizumab combination therapy</arm_group_label>
    <arm_group_label>Chemotherapy doublet</arm_group_label>
    <arm_group_label>Pembrolizumab monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients diagnosed with stage IV NSCLC (de novo or earlier stage progression to stage&#xD;
        IV), without oncogene-activating mutations eligible for targeted therapy, that are treated&#xD;
        in the first-line setting with either pembrolizumab monotherapy, chemotherapy and&#xD;
        pembrolizumab combination therapy, or chemotherapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult ≥18 years old&#xD;
&#xD;
          -  Patient diagnosed with Stage IV NSCLC (de novo or earlier stage progression to stage&#xD;
             IV)&#xD;
&#xD;
          -  Absence of oncogene activating mutations eligible patients to targeted therapy (EGFR,&#xD;
             ALK)&#xD;
&#xD;
          -  Cohort A: Received first line treatment with pembrolizumab monotherapy&#xD;
&#xD;
          -  Cohort B: Received first line treatment with chemotherapy and pembrolizumab&#xD;
             combination therapy&#xD;
&#xD;
          -  Cohort C: Received first line treatment with chemotherapy doublet&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior anti-cancer therapy for actual stage IV NSCLC&#xD;
&#xD;
          -  Critical data missing (e.g., PD-L1 status, baseline millimetric imaging, first&#xD;
             evaluation millimetric imaging)&#xD;
&#xD;
          -  Patients participating in other clinical trials that modify the standard of care&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Menu, MD-PhD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>SOPHiA GENETICS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe Menu, MD-PhD, MBA</last_name>
    <phone>+41216941060</phone>
    <email>DeepLungIV@sophiagenetics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center at University of Iowa Health Care</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carbone Comprehensive Cancer Center at University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre Toronto</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Avicenne Hospital</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boris Duchemann, MD</last_name>
      <email>boris.duchemann@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ambroise Paré Hospital</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne Giroux-Leprieur, Pr</last_name>
      <email>etienne.giroux-leprieur@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sébastien Couraud, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elvire Pons-Tostivint, MD</last_name>
      <email>elvire.pons@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tenon Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Cadranel, Pr</last_name>
      <email>jacques.cadranel@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Foch Hospital</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Perrine Créquit, MD</last_name>
      <email>p.crequit@hopital-foch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Toulon</name>
      <address>
        <city>Toulon</city>
        <zip>83100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clarisse Audigier-Valette, MD</last_name>
      <email>clarisse.audigier-valette@ch-toulon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shaare Zadek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2022</verification_date>
  <study_first_submitted>July 15, 2021</study_first_submitted>
  <study_first_submitted_qc>August 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>January 25, 2022</last_update_submitted>
  <last_update_submitted_qc>January 25, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Predictive models</keyword>
  <keyword>Radiomics</keyword>
  <keyword>Multimodal</keyword>
  <keyword>Genomics</keyword>
  <keyword>Machine learning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

